OTCPK:GENX

Stock Analysis Report

Executive Summary

Genex Pharmaceutical, Inc. produces and distributes Reconstituted Bone Xenograft (RBX) in the People’s Republic of China.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Genex Pharmaceutical's last earnings update was 4132 days ago.
  • Genex Pharmaceutical is not covered by any analysts.

Share Price & News

How has Genex Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-12.5%

OTCPK:GENX

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

n/a

OTCPK:GENX

9.1%

US Medical Equipment

2.0%

US Market

No trading data on GENX.

No trading data on GENX.


Share holder returns

GENXIndustryMarket
7 Day-12.5%-0.9%1.3%
30 Day-12.5%0.7%3.9%
90 Dayn/a4.4%3.4%
1 Yearn/a10.0%9.1%4.2%2.0%
3 Yearn/a70.7%65.5%47.2%37.6%
5 Year-30.0%-30.0%130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is Genex Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Genex Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Genex Pharmaceutical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Genex Pharmaceutical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Genex Pharmaceutical's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Genex Pharmaceutical regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Genex Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genex Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Genex Pharmaceutical performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Genex Pharmaceutical has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Genex Pharmaceutical's financial position?


In this section we usually analyse Genex Pharmaceutical's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Genex Pharmaceutical has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of GENX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Genex Pharmaceutical's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Genex Pharmaceutical's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Genex Pharmaceutical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Genex Pharmaceutical's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Genex Pharmaceutical has not reported any payouts.

Unable to verify if Genex Pharmaceutical's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Genex Pharmaceutical has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Genex Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

US$30k

CEO Compensation


CEO

Fuzhi Song (67yo)

15.3yrs

Tenure

US$29,536

Compensation

Fuzhi Song has been the Chairman, President and Chief Executive Officer of Genex Pharmaceutical Inc. since June 17, 2004. Mr. Song has been General Manager of Jinshi Group from December 1999. He served as  ...


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • Fuzhi Song (67yo)

    Chairman

    • Tenure: 15.3yrs
    • Compensation: US$29.54k
  • Shuli Zhang (57yo)

    CFO, Principal Accounting Officer

    • Tenure: 0yrs
    • Compensation: US$19.70k
  • Sufen Ail (44yo)

    Secretary

    • Tenure: 15.3yrs

Board Members

  • Fuzhi Song (67yo)

    Chairman

    • Tenure: 15.3yrs
    • Compensation: US$29.54k

Company Information

Genex Pharmaceutical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Genex Pharmaceutical, Inc.
  • Ticker: GENX
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$124.922k
  • Shares outstanding: 17.85m
  • Website: https://null

Number of Employees


Location

  • Genex Pharmaceutical, Inc.
  • 1801 Guangyin Building
  • Youyibeilu Hexi District
  • Tianjin City
  • 300074
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GENXOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJun 2004

Biography

Genex Pharmaceutical, Inc. produces and distributes Reconstituted Bone Xenograft (RBX) in the People’s Republic of China. The RBX is a medical device that accelerates bone healing. The company distributes  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 23:51
End of Day Share Price2019/09/13 00:00
Earnings2007/12/31
Annual Earnings2007/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.